Altimmune (NASDAQ:ALT) Coverage Initiated by Analysts at Stifel Nicolaus

Analysts at Stifel Nicolaus began coverage on shares of Altimmune (NASDAQ:ALT) in a research report issued to clients and investors on Wednesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $18.00 price target on the stock. Stifel Nicolaus’ price target suggests a potential upside of 141.61% from the company’s previous close.

Other analysts also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research report on Thursday, November 14th. UBS Group assumed coverage on shares of Altimmune in a research note on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.71.

Altimmune Trading Up 1.9 %

Shares of NASDAQ:ALT opened at $7.45 on Wednesday. Altimmune has a 52 week low of $5.28 and a 52 week high of $14.84. The company’s 50 day moving average is $8.10 and its two-hundred day moving average is $7.20. The company has a market cap of $529.88 million, a PE ratio of -4.81 and a beta of 0.22.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. The company had revenue of $0.01 million for the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same quarter in the prior year, the business earned ($0.39) earnings per share. As a group, equities research analysts expect that Altimmune will post -1.36 EPS for the current year.

Hedge Funds Weigh In On Altimmune

Hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in shares of Altimmune by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock valued at $10,244,000 after buying an additional 74,194 shares during the period. Bellevue Group AG boosted its position in shares of Altimmune by 43.9% during the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock worth $5,303,000 after purchasing an additional 263,660 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Altimmune by 142.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock worth $3,791,000 after purchasing an additional 335,444 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Altimmune by 28.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 243,808 shares of the company’s stock worth $1,621,000 after purchasing an additional 54,154 shares during the period. Finally, Exchange Traded Concepts LLC increased its holdings in shares of Altimmune by 74.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company’s stock valued at $1,331,000 after purchasing an additional 92,498 shares in the last quarter. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.